Semaglutide News and Research

Latest Semaglutide News and Research

Researchers discover how GLP-2 receptor suppresses hunger and food intake

Researchers have discovered how a hormone in the gut slows the rate at which the stomach empties and thus suppresses hunger and food intake. Results of the animal study will be presented Monday at The Endocrine Society's 94th Annual Meeting in Houston.

26 Jun 2012

Positive results from Lexicon’s LX4211 Phase 2b trial on type 2 diabetes

Lexicon Pharmaceuticals, Inc., announced today that LX4211, an investigational, oral, dual inhibitor of sodium glucose transporters 1 and 2 (SGLT1 and SGLT2), showed substantial, dose-dependent, statistically-significant reductions in hemoglobin A1c (HbA1c) in a Phase 2b trial in patients diagnosed with poorly-controlled type 2 diabetes who were concurrently treated with metformin, an established diabetes therapy.

25 Jun 2012

European CHMP adopts positive opinion for teduglutide to treat short bowel syndrome

Takeda Pharmaceutical Company Limited and NPS Pharmaceuticals, Inc., jointly announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product teduglutide (Revestive) as a once-daily treatment for adult patients with short bowel syndrome (SBS).

22 Jun 2012

Shanghai Institutes of Preventative Medicine, Gentris sign MOU to advance personalized medicine

Gentris Corporation, a global leader in the application of genomic biomarkers to clinical studies, announced today that it has signed a Memorandum of Understanding with the Shanghai Institutes of Preventative Medicine to advance global personalized medicine.

22 Jun 2012

Arrowhead initiates final IND-enabling steps for ARC-520 to treat HBV

Arrowhead Research Corporation, a targeted therapeutics company, today announced that its hepatitis B virus (HBV) program has completed all internal preclinical requirements and has named a clinical candidate.

7 Jun 2012

GLP-1 receptor agonist boosts glycemic control in Asian patients

Adding once-daily lixisenatide to basal insulin treatment is effective at improving glycemic control in Asian patients with Type 2 diabetes, show study findings.

6 Jun 2012

PhaseBio raises $48.4M in Series B financing

PhaseBio Pharmaceuticals, Inc., a privately held, clinical-stage biotechnology company developing drugs to treat diabetes, metabolic disease and cardiovascular disease, announced today that it has raised a total of $48.4 million from its Series B financing following receipt of the third tranche to advance the company's product development programs.

6 Jun 2012

Gattex may represent new treatment approach for short bowel syndrome

NPS Pharmaceuticals, Inc., a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, today reported the presentation of data at the Digestive Disease Week (DDW) meeting held May 19-22 in San Diego.

22 May 2012

Cardionovum to introduce two DEB dilatation catheter product families

Cardionovum GmbH will launch two drug-eluting balloon (DEB) dilatation catheter product families at next week's EuroPCR 2012 congress: Paclitaxel-coated drug-eluting balloons for coronary and peripheral applications.

11 May 2012

BioCryst first quarter revenues increase to $12.2 million

BioCryst Pharmaceuticals, Inc. announced financial results for the first quarter ended March 31, 2012.

7 May 2012

FDA issues complete response letter to Takeda’s NDAs for type 2 diabetes investigational therapies

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Global Research & Development Center, Inc. today announced that the company received a complete response letter from the United States (U.S.) Food and Drug Administration (FDA) regarding New Drug Applications (NDAs) for alogliptin and fixed-dose combination (FDC) alogliptin and pioglitazone.

26 Apr 2012

Tengion completes FDA Pre-IND meeting for Neo-Kidney Augment preclinical program

Tengion, Inc., a leader in regenerative medicine, today announced that it recently completed a successful Pre-IND meeting with the U.S. Food and Drug Administration (FDA) for its lead preclinical program, the Neo-Kidney Augment.

18 Apr 2012

MTPC, Medicago partner to develop and commercialize three new vaccines

Medicago Inc., a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced the establishment of a strategic alliance with Mitsubishi Tanabe Pharma Corporation (MTPC) through the execution of a Master Research Collaboration Agreement.

6 Mar 2012

Agilux implements Thermo Watson LIMS for bioanalytical services

Agilux Laboratories, a provider of pharmaceutical and biotech services, today announced that it has completed the validation and implementation of the Thermo Watson Laboratory Information Management System (LIMS) for the company's bioanalytical services.

13 Jan 2012

Amylin outlines key strategic priorities for 2012

Amylin Pharmaceuticals, Inc. today outlined its key strategic priorities for 2012, with a strong focus on driving the global commercial value of its diabetes franchise.

10 Jan 2012

INT-777 shows promise against metabolic syndrome

Heart disease is a major cause of death in industrialised countries, and is strongly associated with obesity and diabetes. Many scientists believe that what links these conditions is a chronic, low-grade inflammation.

7 Dec 2011

Takeda submits alogliptin plus metformin NDA to FDA for treatment of type 2 diabetes

Takeda Pharmaceutical Company Limited (Takeda) announced today that its wholly-owned subsidiary Takeda Global Research & Development Center, Inc., U.S., submitted a New Drug Application (NDA) to the United States (U.S.) Food and Drug Administration (FDA) for the fixed-dose combination therapy alogliptin/metformin, which combines alogliptin with metformin in a single tablet.

24 Nov 2011

FDA assigns new PDUFA date for Takeda's investigational type 2 diabetes therapy, alogliptin

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Global Research & Development Center, Inc., U.S., today announced that the company received notification from the U.S. Food and Drug Administration (FDA) that its review of investigational type 2 diabetes therapy alogliptin, and thus the fixed-dose combination therapy alogliptin/pioglitazone, will be delayed.

18 Nov 2011

Midatech receives Swissmedic approval to start trial of insulin-coated gold nanoparticle

Midatech Ltd., a global leader in the design, development, synthesis and manufacture of nanomedicines, announced today it has received Swissmedic approval to start the First-in-Human clinical trial with insulin-coated gold nanoparticles, which will be coordinated through its Swiss subsidiary PharMida AG.

15 Nov 2011

Amylin and Lilly terminate exenatide alliance, resolve litigation

Amylin Pharmaceuticals, Inc. and Eli Lilly and Company today announced an agreement to terminate their alliance for exenatide and resolve the outstanding litigation between the companies.

9 Nov 2011